The Moleculin Biotech (MBRX) Earning Somewhat Favorable Press Coverage, Study Finds

Paterniano Del Favero
Agosto 15, 2017

With 83,600 shares average volume, it will take short sellers 9 days to cover their MBRX's short positions. Based on an average daily volume of 1,890,021 shares, the short-interest ratio is now 0.7 days.

A hedge fund recently raised its stake in Moleculin Biotech stock. Moleculin Biotech Inc (NASDAQ:MBRX) has 0.00% since August 14, 2016 and is. 439,061 shares of the company's stock were exchanged. Virtu KCG Holdings LLC owned approximately 2.04% of Moleculin Biotech worth $676,000 at the end of the most recent quarter.

Moleculin Biotech (MBRX) traded down 5.90% during midday trading on Friday, hitting $2.71. Moleculin Biotech earned a coverage optimism score of 0.08 on Accern's scale. The stock has a 50-day moving average of $1.89 and a 200-day moving average of $1.33. The company has market cap of $44.75 million.

More important recent Moleculin Biotech Inc (NASDAQ:MBRX) news were published by: Marketwired.com which released: "Moleculin's New Drug for the Treatment of Glioblastoma Nears Clinical Trials ..." on July 25, 2017, also Marketwired.com published article titled: "Moleculin Strengthens Board of Directors with Appointment of John M. Climaco", Marketwired.com published: "Moleculin Biotech, Inc". The company reported ($0.02) EPS for the quarter. Equities analysts forecast that Moleculin Biotech will post ($0.34) earnings per share for the current fiscal year.

Separately, ValuEngine lowered shares of Moleculin Biotech from a "sell" rating to a "strong sell" rating in a research report on Tuesday, June 6th.

WARNING: This piece was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another domain, it was stolen and republished in violation of US & worldwide copyright and trademark laws.

Moleculin Biotech, Inc.is a preclinical-stage pharmaceutical company. The Firm is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).

Altre relazioni OverNewsmagazine

Discuti questo articolo

SEGUI I NOSTRI GIORNALE